Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1
Hardik Chandasana(Simulation Technologies (United States)), Tim R. Cressey, Sven C. van Dijkman, Rashmi Mehta, Helena Rabie(Stellenbosch University), Kristina M. Brooks(National Institutes of Health Clinical Center), Mark Bush(Research Triangle Park Foundation), Patricia M. Flynn(St. Jude Children's Research Hospital), Edward P. Acosta(University of Alabama at Birmingham)
Cited by 3
Related Papers
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
|The Lancet|2022|16k
Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.6k
Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant
|New England Journal of Medicine|1996|817
MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs
|Nature Medicine|1999|580
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
|Journal of Clinical Investigation|2018|519